Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 14;78(6):1698-1706.
doi: 10.1093/cid/ciae145.

Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study

Hannah Morgan  1 , Norbert Ndjeka  2 , Tasnim Hasan  1 , Medea Gegia  3 , Fuad Mirzayev  3 , Linh N Nguyen  3 , Samuel Schumacher  3 , Timothy E Schlub  1 , Kogieleum Naidoo  4 , Greg J Fox  1
Affiliations

Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study

Hannah Morgan et al. Clin Infect Dis. .

Abstract

Background: In 2019, the South African tuberculosis program replaced ethionamide with linezolid as part of an all-oral 9-month regimen. We evaluated treatment outcomes for patients assigned to regimens including linezolid in 2019 and ethionamide in 2017.

Methods: This retrospective cohort study included patients treated for multidrug-resistant/rifampicin-resistant tuberculosis throughout South Africa between 1 January and 31 December 2017 and 1 January to 31 December 2019. The cohort treated with a 9-month regimen containing ethionamide for four months, was compared with a cohort treated with a 9-month regimen containing linezolid for 2 months. The regimens were otherwise identical. Inverse probability weighting of propensity scores was used to adjust for potential confounding. A log-binomial regression model was used to estimate adjusted relative risk (aRR) comparing 24-month outcomes between cohorts including treatment success, death, loss to follow up, and treatment failure. Adverse event data were available for the linezolid cohort.

Findings: In total, 817 patients were included in the cohort receiving ethionamide and 4244 in the cohort receiving linezolid. No evidence for a difference was observed between linezolid and ethionamide regimens for treatment success (aRR = 0.96, 95% confidence interval [CI] .91-1.01), death (aRR = 1.01, 95% CI .87-1.17) or treatment failure (aRR = 0.87, 95% CI .44-1.75). Loss to follow-up was more common in the linezolid group, although estimates were imprecise (aRR = 1.22, 95% CI .99-1.50).

Conclusions: No significant differences in treatment success and survival were observed with substitution of linezolid for ethionamide as a part of an all-oral 9-month regimen. Linezolid is an acceptable alternative to ethionamide in this shorter regimen for treatment of multidrug-resistant/rifampicin-resistant tuberculosis.

Keywords: all-oral 9-month regimen; ethionamide; linezolid; multidrug- resistant tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Flow diagram of selection of study participants from patients notified with RR-TB allocated to a 9-month regimen within the South Africa national TB program. Abbreviations: MDR-TB, multidrug-resistant tuberculosis; RR-TB, rifampicin-resistant tuberculosis; TB, tuberculosis.
See this image and copyright information in PMC

References

    1. World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment—drug-resistant tuberculosis treatment, 2020. 2020. Available at: https://www.who.int/publications/i/item/9789240007048. Accessed 6 January 2023. - PubMed
    1. World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment—drug-resistant tuberculosis treatment, 2022 update. 2022. Available at: https://www.who.int/publications/i/item/9789240063129. Accessed 6 January 2023. - PubMed
    1. Ndjeka N, Campbell JR, Meintjes G, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis 2022; 22:1042–51. - PMC - PubMed
    1. Ndjeka N, Hughes J, Reuter A, et al. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn? Int J Tuberc Lung Dis 2020; 24:1073–80. - PubMed
    1. National Department of Health, South Africa . Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children. 2018. Available at: https://www.tbonline.info/media/uploads/documents/dr_tb_clinical_guideli.... Accessed 6 January 2023.

Publication types

MeSH terms